EXCLUSIVE: Nexalin Tells Benzinga New Study Shows Co's Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory And Cognitive Function In Alzheimer's Patients
Portfolio Pulse from Benzinga Newsdesk
Nexalin Technology has announced a new study showing that its Deep Intracranial Frequency Stimulation (DIFS) significantly improves memory and cognitive function in Alzheimer's patients. This development could have positive implications for the company's future prospects.
October 17, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nexalin Technology's study on DIFS shows significant improvements in Alzheimer's patients' memory and cognitive function, potentially boosting the company's market position and stock price.
The study's positive results could enhance Nexalin's reputation and marketability in the Alzheimer's treatment space, likely leading to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90